Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Safety and efficacy of teclistamab in patients with triple-class exposed R/R myeloma

Hermann Einsele • 11 Jun 2022
EHA 2022
Multiple Myeloma BiTEs Teclistamab
MajesTEC-1

Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, shares some insights into the safety and efficacy of teclistamab in patients with triple-class exposed relapsed/refractory (R/R) myeloma as observed in the MajesTEC-1 trial (NCT04557098), and further highlights the importance of optimizing treatment with this bispecific T-cell engager (BiTE). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Hermann Einsele

2:44
Moving CAR-T into earlier lines of therapy in multiple myeloma
Hermann Einsele • 17 Feb 2024
0:45
CAR T-cell therapy in lenalidomide-refractory multiple myeloma
Hermann Einsele • 17 Feb 2024
1:19
Sequencing bispecific antibodies and CAR-T therapy & the evolving role of bispecifics in myeloma
Hermann Einsele • 26 Jun 2023
8:16
Results from CARTITUDE-4: cilta-cel for lenalidomide-refractory multiple myeloma
Hermann Einsele • 26 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals